Checking women with HIV in Sweden for early anal cancer changes
Tests anal HPV screening in women aged 45 or older living with HIV.
Plain-language title generated from the registry record
Registry title: Screening for Anal Cancer and Precancer in Women With HIV (SANCA)
Key facts
- Where
- Stockholm, SwedenSee the site
Where in Sweden
- Karolinska InstitutetStockholm, SwedenNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Karolinska Institutet
- Trial code
- NCT07059442
- Record updated
- 10 July 2025
- Original description
The main aim of the SANCA study is to evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women living with HIV in Sweden, integrating health economic and patient-centered approaches.Read full original descriptionShow less
Screening for Anal Cancer and Precancer in Women With HIV (SANCA)
The main aim of the SANCA study is to evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women living with HIV in Sweden, integrating health economic and patient-centered approaches.
Secondly the investigators wish to investigate the predictive potential of DNA methylation markers for the clinical progression of precancerous anal lesions in women with HIV, combining prospective molecular biology analysis with clinical data from registries.
Inclusion: Women (biological sex) with HIV; 45 years old or older; attending the out-patient HIV departments at Karolinska University Hospital in Stockholm, the South Hospital in Stockholm, and Sahlgrenska University Hospital in Gothenburg.
Exclusion: Women who have had anal cancer; women who have had rectal amputation.